# Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

> **NCT02246764** · PHASE3 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 93 (actual)

## Conditions studied

- Ocular Hypertension
- Glaucoma

## Interventions

- **DRUG:** AR-13324 Ophthalmic Solution 0.02%
- **DRUG:** AR-13324 Ophthalmic Solution 0.02% BID
- **DRUG:** Timolol maleate Ophthalmic Solution 0.5% BID
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02246764
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2018-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02246764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02246764, "Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02246764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*